Skip to content

Advertisement

  • Research
  • Open Access

Heparin-binding protein in ventilator-induced lung injury

Intensive Care Medicine Experimental20186:33

https://doi.org/10.1186/s40635-018-0198-x

  • Received: 4 May 2018
  • Accepted: 3 September 2018
  • Published:

Abstract

Background

Although mechanical ventilation is often lifesaving, it can also cause injury to the lungs. The lung injury is caused by not only high pressure and mechanical forces but also by inflammatory processes that are not fully understood. Heparin-binding protein (HBP), released by activated granulocytes, has been indicated as a possible mediator of increased vascular permeability in the lung injury associated with trauma and sepsis. We investigated if HBP levels were increased in the bronchoalveolar lavage fluid (BALF) or plasma in a pig model of ventilator-induced lung injury (VILI). We also investigated if HBP was present in BALF from healthy volunteers and in intubated patients in the intensive care unit (ICU).

Methods

Anaesthetized pigs were randomized to receive ventilation with either tidal volumes of 8 ml/kg (controls, n = 6) or 20 ml/kg (VILI group, n = 6). Plasma and BALF samples were taken at 0, 1, 2, 4, and 6 h. In humans, HBP levels in BALF were sampled from 16 healthy volunteers and from 10 intubated patients being cared for in the ICU.

Results

Plasma levels of HBP did not differ between pigs in the control and VILI groups. The median HBP levels in BALF were higher in the VILI group after 6 h of ventilation compared to those in the controls (1144 ng/ml (IQR 359–1636 ng/ml) versus 89 ng/ml (IQR 33–191 ng/ml) ng/ml, respectively, p = 0.02).

The median HBP level in BALF from healthy volunteers was 0.90 ng/ml (IQR 0.79–1.01 ng/ml) as compared to 1959 ng/ml (IQR 612–3306 ng/ml) from intubated ICU patients (p < 0.001).

Conclusions

In a model of VILI in pigs, levels of HBP in BALF increased over time compared to controls, while plasma levels did not differ between the two groups.

HBP in BALF was high in intubated ICU patients in spite of the seemingly non-harmful ventilation, suggesting that inflammation from other causes might increase HBP levels.

Keywords

  • Ventilator-induced lung injury
  • HBP
  • Pigs
  • Neutrophils

Background

Respiratory failure requiring mechanical ventilation is a common reason for admission to intensive care units (ICUs). While lifesaving, mechanical ventilation can in itself cause injury to lung tissue [1, 2].

The lung injury caused by mechanical ventilation is in part due to barotrauma and mechanotrauma, and triggering of an inflammatory process in the lungs plays an important role in worsening the injury. This is sometimes referred to as biotrauma [3]. Central parts of this inflammatory process depend on neutrophil activity, and a dominant feature of the lung injury is increased vascular permeability causing pulmonary oedema [3]. It has been shown that leukocyte depletion attenuates ventilator-induced lung injury (VILI) [4]. While it is well known that release of, for example, tumour necrosis factor alpha, interleukin 6, and interleukin 1-beta are associated with VILI, the mechanism by which leukocytes cause lung injury is not fully understood [1, 3].

Heparin-binding protein (HBP) is a protein found in the vesicles of neutrophil granulocytes. It has been shown to have several properties contributing to the inflammatory process, and its ability to increase vascular permeability in critically ill patients has been the focus of several recent studies [57]. Plasma levels of HBP have been found to be elevated in patients with acute respiratory distress syndrome and respiratory impairment after trauma, sepsis, and in mixed ICU patients [5, 810]. Increased HBP levels have also previously been shown to be associated with circulatory failure, renal failure, and mortality in critically ill patients [57, 1014].

HBP levels in the bronchoalveolar fluid (BALF) have not previously been studied, and whether HBP plays a role in VILI has, to our knowledge, not been studied previously.

We hypothesized that HBP is an important mediator of leukocyte-mediated lung injury associated with harmful mechanical ventilation, and we hypothesized that levels of HBP in plasma and BALF would be elevated in a pig model of VILI. Further, we investigated if HBP was present in BALF in intubated ICU patients and in healthy volunteers, with the purpose of getting an indication as to whether the results from the animal model might be relevant in humans.

Methods

Animals studies

Twelve juvenile Yorkshire/Swedish landrace pigs with a mean weight of 35.5 ± 9.7 kg were used.

Preparation

Premedication was administered with intramuscular ketamine 10 mg/kg (Ketalar® 10 mg/ml, Pfizer AB, Sweden), xylazine 2.2 mg/kg (Rompun® vet 20 mg/ml, Bayer Animal Health, Denmark), and atropine sulphate 0.05 mg/kg (Atropine® Mylan 0.5 mg/ml, Mylan AB, Sweden). An induction dose of intravenous pentobarbital 10 mg/kg (pentobarbitalnatrium, Apoteksbolaget, Stockholm, Sweden) was given, and anaesthesia was maintained by an infusion of fentanyl 20 μg/kg/h (fentanyl, Braun, Melsungen, Germany), midazolam 0.3 mg/kg/h (Dormicum, Roche, Basel, Switzerland), and pentobarbital 5 mg/kg/h. After orotracheal intubation, the animals were mechanically ventilated (Evita 4, Dräger, Kiel, Germany) with 8 ml/kg tidal volume, ratio of inspiration/expiration (I:E) 1:2, PEEP (positive end-expiratory pressure) 5 cm H2O, FiO2 0.4, and respiratory rate set to maintain normocapnia. Under sterile conditions, a central venous line was percutaneously inserted through the external jugular vein and an arterial line was placed in the carotid artery after a cutdown procedure. Ringer’s acetate (Ringer-Acetat® Baxter Viaflo, Baxter Medical AB, Sweden) was given at a rate of 4–5 ml/kg/h. If hypovolemia was suspected, a bolus of 250 ml of hydroxyethyl starch solution (Voluven®, Fresenius-Kabi, Uppsala, Sweden) was administered.

A warming gel pad was used to maintain a steady body temperature of 38.0 °C, as measured per rectum.

Protocol

To render the animals’ lungs more susceptible to VILI, surfactant depletion was performed by saline lavage in all animals. After preoxygenation with FiO2 1.0, 30 ml/kg of 38 °C 0.9% sterile normal saline was instilled into the trachea and then allowed to drain passively through the tracheal tube. The procedure was repeated a total of four times, interspaced by a short recovery period to allow the arterial oxygen saturation to return to at least 96%.

Immediately after surfactant depletion, the animals were randomized to either protective or injurious ventilation. In the group with protective ventilation, tidal volumes were kept at 8 ml/kg with I:E 1:2 and PEEP was elevated to 8 cm H20. Respiratory rate was adjusted to normocapnia, and FiO2 was set to achieve normoxia. The group with injurious ventilation (referred to as the VILI group) received tidal volumes of 20 ml/kg with I:E 1:2, respiratory rate 20 bpm, ZEEP (zero end-expiratory pressure), and FiO2 1.0. Extra tubing was added as needed between the endotracheal tube and the Y-piece to increase the dead space to aim for normocapnia. The animals were ventilated in either fashion for 6 h and then euthanized by injection of potassium chloride under continuous deep anaesthesia. Samples of blood and BALF were collected before surfactant depletion and after 1, 2, 4, and 6 h of ventilation (Fig. 1).
Fig. 1
Fig. 1

Schematic overview of the protocol. BAL bronchoalveolar lavage, TV tidal volume, PEEP positive end-expiratory pressure

Biopsies from the upper and lower lobes of both lungs were collected during autopsy. The histology of the biopsies was examined by a pathologist, blinded to group assignment, evaluating acute lung injury looking at oedema, bleeding, membranes, alveolar inflammation, and bronchiolitis. The severity of lung injury was graded as no, mild, moderate, or severe.

Sampling procedures

BALF was collected using a flexible fiberoptic bronchoscope. The bronchoscope was inserted through the tracheal tube and carefully wedged into a bronchus. As sampling was repeated, care was taken to avoid multiple samples from the same location. Three aliquots of 50 ml sterile saline were infused and gently suctioned back after each infusion. The BALF was recovered in a glass container placed in ice water. After immediate filtration through a 100-μm nylon filter, the recovered volume was noted and the BALF was centrifuged for 15 min at 4 °C at 400 RCF. The supernatants were separated from the cell pellet, divided into aliquots, and immediately frozen at − 70 °C. The cell pellets were resuspended in phosphate-buffered saline at a cell concentration of 106 cells/mL for differential cell counts.

Blood samples were collected from the arterial line using standard EDTA vacutainer tubes. The blood samples were immediately put on ice and centrifuged for 10 min at 4 °C at 2000 RCF. The plasma was then recovered and immediately frozen in aliquots at − 70 °C.

Human studies

Healthy volunteers

Sixteen healthy, non-smoking subjects were recruited to the study.

The subjects received 1 mg atropine subcutaneously as pre-medication. Lidocaine was used for topical anaesthesia. Bronchoscopy was performed using a flexible video bronchoscope (Olympus BF IT200; Olympus, Tokyo, Japan) introduced through the mouth. Bronchoalveolar lavage (BAL) with 3 × 60 ml of saline solution from the middle or lingula lobes was performed. The recovered aspirate was filtered to eliminate mucus (pore diameter 100 μm) and centrifuged at 400×g for 15 min to separate the cellular components from the supernatant, which was stored at − 80 °C until analysis.

ICU patients

Ten patients older than 18 years of age admitted to the ICU of Östersund Hospital and intubated during the previous 24-h period were included.

The SAPS 3 at admission to the ICU and the highest respiratory pressure settings from intubation to sampling were recorded. Plasma levels of HBP were sampled at the time of intubation. Diagnosis was determined retrospectively through chart review.

BALF was collected using a flexible fiberoptic bronchoscope. The bronchoscope was inserted through the tracheal tube and wedged into a bronchus of the middle or lingual lobe. If lung pathology was unilateral, the contralateral side was used. A total volume of 50 ml of sterile saline was instilled and suctioned back four times. The obtained fluid was filtered and centrifuged at 400×g, and the supernatant was frozen at − 80 °C until analysis.

Analysis of HBP

Concentrations of HBP in the samples were measured as described previously [15]. In short, a sandwich ELISA with a monoclonal and polyclonal antibody against pig or human HBP was used to measure the concentrations. The technique has an intra- and inter-assay variability of less than 10%.

Statistics

Descriptive data are presented as medians with interquartile ranges. Because the data were not normally distributed, the Mann–Whitney U test or related samples Wilcoxon signed-rank test was used for comparison between groups as appropriate. The significance of differences between categorical variables was evaluated using Fisher’s exact test. Probabilities of less than 0.05 were accepted as significant. The data were analysed using SPSS (IBM SPSS Statistics for Macintosh, Version 23.0, Armonk, NY: IBM Corp).

Results

Animal studies

As intended, the VILI group received significantly higher FiO2, larger tidal volumes, and higher inspiratory pressures and had lower respiratory rates compared to the control group. Oxygenation was significantly impaired in the VILI group. Arterial carbon dioxide levels were not significantly different between the groups, whereas the pH was lower in the VILI group. The average total fluid administration per hour was higher in the VILI group. There were two premature deaths during the experiment in the VILI group, and none in the control group. Other baseline characteristics and physiological measurements were similar between the two groups (Table 1).
Table 1

Characteristics of the pigs by study group. Data are presented as the median (interquartile range)

 

Control n = 6

VILI n = 6

p value

Weight (kg)

35.5 (28–50)

35.5 (29–47)

0.818

Premature death (n)

0

2

 

Tidal volume (ml)

280 (228–400)

710 (575–940)

0.002*

Respiratory rate (breaths/min)

30 (26–38)

20 (20–20)

0.002*

Average peak inspiratory pressure (cmH2O)

22 (20–23)

43(39–48)

0.002*

FiO2

0.35 (0.29–0.40)

1.0 (1.0–1.0)

0.002*

Worst P/F ratio (kPa)

46 (34–52)

14 (8–39)

0.041*

Last P/F ratio

53 (43–64)

25 (8–43)

0.065

Last PCO2 (kPa)

4.6 (3.8–5.0)

5.9 (4.7–7.0)

0.093

Last pH

7.52 (7.47–7.55)

7.41 (7.31–7.48)

0.026*

Total crystalloid (ml)

2000 (975–3000)

2500 (1800–3200)

0.394

Total colloid (ml)

0 (0–500)

375 (0–500)

0.485

Average fluid admin. (ml/kg/h)

7.7 (4.4–8.2)

10.0 (8.5–12.0)

0.026*

Average CVP (mmHg)

8 (7–8)

7 (6–9)

0.394

Average MAP (mmHg)

70 (67–75)

75 (53–102)

0.24

Average heart rate (bpm)

87 (82–95)

103 (94–111)

0.065

Average temp (°C)

39.4 (38.3–39.7)

38.5 (38.0–39.3)

0.394

Recovered BALF volume (%)

78 (62.5–84.0)

71 (60.0–79.0)

0.168

FiO2 fraction of oxygen in inspired gas, P/F ratio ratio between partial pressure of oxygen in arterial blood (kPa) and simultaneous FiO2, PCO2 partial pressure of carbon dioxide in arterial blood, CVP central venous pressure, MAP mean arterial pressure, BALF bronchoalveolar lavage fluid

Asterisks indicate statistical significance (p < 0.05)

In the VILI group, 2 biopsies were lost or damaged. Out of the remaining 34, none showed no lung injury, 1 showed mild lung injury, 10 showed moderate lung injury, and 23 showed severe lung injury. In the control group, 5 biopsies were lost or damaged. Out of the remaining 24, 14 showed no lung injury, 4 showed mild lung injury, 1 showed moderate lung injury, and none showed severe lung injury.

There were significantly more biopsies showing severe (p < 0.01) and moderate (p = 0.047) lung injury in the VILI group. There were significantly more biopsies showing no lung injury (p < 0.01) in the control group.

HBP levels in plasma did not differ significantly between the groups at any time of sampling (Table 2). HBP levels in BALF were significantly higher in the VILI group after 1 h (p = 0.04), 2 h (p = 0.03), 4 h (p < 0.01), and 6 h (p = 0.02) of ventilation (Table 2, Fig. 2).
Table 2

Levels of heparin-binding protein and neutrophil counts in pigs subjected to injurious ventilation and controls

Baseline

HBP in BALF (ng/ml)

HBP in plasma (ng/ml)

Neutrophil count in BALF (×104/ml)

Control

VILI

p

Control

VILI

p

Control

VILI

p

 

45 (32–216)

17 (14–18)

0.01

23 (16–29)

21 (20–25)

0.84

1.1 (0.5–2.0)

0.9 (0.2–1.4)

0.49

1 h

20 (18–23)

29 (20–43)

0.04*

31 (21–58)

23 (19–34)

0.70

1.0 (0.7–1.2)

1.4 (0.8–2.5)

0.39

2 h

25 (19–42)

147 (62–453)

0.03*

25 (18–31)

24 (18–36)

0.69

1.3 (0.6–2.2)

6.3 (4.6–12.6)

< 0.01*

4 h

22 (17–235)

859 (250–1475)

< 0.01*

28 (24–39)

35 (23–39)

0.94

1.7 (0.8–4.1)

22.1 (6.6–28.2)

0.05

6 h

89 (33–191)

1144 (359–1636)

0.02*

33 (31–44)

61 (47–77)

0.13

2.7 (2.2–2.8)

21.0 (6.1–33.7)

0.03*

Data are presented as the median (interquartile range). Asterisks indicate statistical significance (p < 0.05)

HBP heparin-binding protein, BALF bronchoalveolar lavage fluid, VILI ventilator-induced lung injury

Fig. 2
Fig. 2

Levels of heparin-binding protein (HBP) (ng/ml) in the bronchoalveolar lavage (BAL) fluid from pigs. HBP levels were significantly higher in the group receiving harmful ventilation at 2 h (p = 0.03), 4 h (p < 0.01), and 6 h (p = 0.02) of ventilation. Boxes indicate the second to third quartile with the median. Brackets indicate min-max values, circles indicate outliers, and stars indicate significant differences (p < 0.05)

In the VILI group, comparing first and last samples, plasma levels of HBP did not increase over time (p = 0.07) whereas HBP levels in BALF increased significantly (p = 0.04).

The neutrophil count in BALF was significantly higher in the VILI group at 2 h (p < 0.01) and 6 h (p = 0.03) of ventilation (Table 2, Fig. 3).
Fig. 3
Fig. 3

Neutrophil count (× 104/ml) in the bronchoalveolar lavage (BAL) fluid. The neutrophil count was significantly higher in the group receiving harmful ventilation at 2 h (p < 0.01) and 6 h (p = 0.03) of ventilation. Boxes indicate the second to third quartile with the median. Brackets indicate the min-max values, circles indicate outliers, and stars indicate significant differences (p < 0.05)

Human studies in healthy volunteers and ICU patients

The diagnoses and respiratory settings of the ICU patients are shown in Table 3. The median HBP level in plasma from the ICU patients was 31.3 ng/ml (IQR 22.4–55.5).
Table 3

Characteristics and levels of HBP in BALF and plasma in intubated ICU patients

Diagnosis

SAPS 3

FiO2 (%)

Peak pressure (cm H2O)

PEEP (cm H2O)

Tidal volume (ml/kg)

HBP level in BALF (ng/ml)

HBP level in plasma (ng/ml)

Pneumococcal sepsis

76

50

26

9

6.3

25

1220

Aspiration pneumonia

65

35

15

8

6.3

1098

23

COPD, pneumonia

91

40

22

9

5.6

1614

17

Staphylococcal pneumonia

83

55

28

11

6.1

1341

24

Fasciitis in extremity

61

45

26

12

6.3

4558

82

Status epilepticus

65

30

14

5

5.6

3254

29

Spinal trauma, delirium

53

35

20

10

7.4

2325

47

Pneumonia

56

50

24

12

5.5

4646

43

Aspiration pneumonia

51

60

17

8

6.8

2303

13

Pneumonia

68

35

15

7

5.9

251

34

SAPS 3 Simplified Acute Physiology Score 3, FiO2 fraction of oxygen in inspired gas, PEEP positive end-expiratory pressure, BALF bronchoalveolar lavage fluid, HBP heparin-binding protein, COPD chronic obstructive pulmonary disease

The median HBP level in BALF from healthy volunteers was 0.90 ng/ml (IQR 0.79–1.01), and the median HBP level in BALF in intubated ICU patients was 1959 ng/ml (IQR 612–3306). The HBP levels in BALF were significantly higher in the ICU patients (p < 0.01).

Discussion

In this study with data from animals and humans, we show that in pigs subjected to VILI, levels of HBP in BALF increased significantly over time, while HBP levels in plasma did not. Human healthy volunteers had low HBP levels in BALF, whereas HBP levels were significantly higher in intubated ICU patients who did not have documented VILI.

The findings imply local release of HBP in the alveoli, thus suggesting a potential pathophysiological contributor in VILI. In pigs subjected to injurious ventilation, the increased number of BALF neutrophils is in line with previous research [1]. Although the presence of several inflammatory mediators in BALF in VILI has been found previously [3], this is, to the best of our knowledge, the first time that levels of HBP have been investigated in this context.

It is highly likely that the HBP found in BALF originates from neutrophils and that the higher levels in the VILI group might simply be related to the finding of more neutrophils in this group. The higher FiO2 in the VILI group might have activated neutrophils and contributed to higher HBP levels.

In the ICU patients (n = 10), HBP levels in BALF were higher compared to the healthy volunteers. This was despite the seemingly non-injurious ventilation. This is probably due to inflammatory processes in the lungs from a variety of causes other than VILI, and thus measuring HBP levels in BALF does not seem to be a way of detecting injurious ventilation in ICU patients.

The plasma levels of HBP in the ICU patients were elevated to a level consistent with previous research on ICU patients with respiratory or circulatory failure [5, 6, 9, 16, 17].

In a recent publication, heparin was found to counteract HBP’s ability to increase vascular permeability in vitro [5]. This, together with several publications on heparin inhalation in acute lung injury with mixed results [1820], points towards a possible way to attenuate lung injury caused by harmful ventilation. This would be an interesting topic for future studies.

Increased extravasation of granulocytes in the alveoli and increased pulmonary vascular permeability are hallmarks of ARDS. The concentrations of HBP found in BALF in ventilated patients in the ICU were very high in comparison with concentrations found in plasma, despite being diluted in the BAL process. Thus, the actual concentration in the alveoli of these patients must have been extremely high, likely by a factor of at least one thousand above what was found in plasma in the same patients. The concentrations of HBP previously used in vitro to affect vascular permeability were in this same range [21]; thus, it is likely that the patients that we studied had increased vascular permeability due to the levels of HBP that were found. Further, in a state of increased vascular permeability, it might be possible for HBP to pass the epithelial and the endothelial membranes. This means that the lungs might indeed be a source of systemic HBP in critical illness.

The pig model we used to study VILI has strengths and weaknesses. Surfactant depletion is rarely clinically relevant in adult critical care. However, since both the control and treatment groups are subjected to lavage and the groups separate well with regard to histology and HBP levels, we believe the results are relevant.

One of the pigs in the group receiving high tidal volumes did not develop histological lung injury nor did it have elevated levels of HBP in plasma or BALF or increased numbers of neutrophils compared to the control group. This is highly interesting, but we do not know why this pig was seemingly resistant to the injurious effects of the high tidal volume ventilation.

Conclusions

In a model of VILI in pigs, the levels of HBP in BALF increased significantly over time compared to controls. Plasma levels, however, did not differ significantly between the two groups.

HBP in BAL fluid was high in intubated ICU patients in spite of the seemingly non-harmful ventilation, suggesting that inflammation from other causes might increase HBP levels.

Abbreviations

BALF: 

Bronchoalveolar lavage fluid

HBP: 

Heparin-binding protein

ICU: 

Intensive care unit

VILI: 

Ventilator-induced lung injury

Declarations

Acknowledgements

We are grateful to the ICU staff at Östersund Hospital for their help in collecting data and the laboratory staff in Östersund, Umeå, and Lund for handling samples.

Funding

The study was partially funded by the Unit of Research, Education and Development—Östersund, Region Jämtland-Härjedalen. It had no role in the design of the study, collection, analysis, or interpretation of data or writing the manuscript.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article and its additional file (Additional file 1).

Authors’ contributions

JT, JJ, NL, SL, and AFB conceived the study and designed and performed the experiments. HH performed the laboratory analyses. The manuscript was drafted by JT, JW, MH, and JJ with contributions from NL, SL, HH, and AFB. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Pigs were used after ethical permission from the Umeå Animal Experimental Ethics Committee (D. nr. A43-12). All procedures were carried out in accordance with the US Public Health Service Policy on Humane Care and Use of Laboratory Animals and the Guide for the Care and Use of Laboratory Animals (1996) prepared by the National Academy of Sciences’ Institute for Laboratory Animal Research.

The study on healthy volunteers was approved by the Umeå University Ethics Committee (D.nr. 2018-30-32M(07-099M)). All subjects gave their written informed consent.

For the ICU patients, the regional ethics review board in Linköping gave ethical approval (D.nr. 2010/427-31, 30/9 2011). Oral consent was given by the next of kin.

Consent for publication

Not applicable.

Competing interests

The company Hansa Medical has filed a patent for HBP as a diagnostic tool in sepsis, and Heiko Herwald is listed as one of the inventors. The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors’ Affiliations

(1)
Department of Surgical and Perioperative Sciences, Anaesthesiology and Critical Care Medicine (Östersund), Umeå University, Umeå, Sweden
(2)
Department of Surgical and Perioperative Sciences, Anaesthesiology and Critical Care Medicine (Umeå), Umeå University, Umeå, Sweden
(3)
Department of Cell and Molecular Biology, Lund University, Lund, Sweden
(4)
Department of Surgical and Perioperative Sciences, Anaesthesiology and Critical Care Medicine (Sundsvall), Umeå University, Umeå, Sweden
(5)
Department of Public Health and Clinical Medicine, Division of Medicine, Umeå University, Umeå, Sweden
(6)
Anestesiläkaravdelningen, Östersund Hospital, 831 32 Östersund, Sweden

References

  1. Slutsky AS, Ranieri VM (2013) Ventilator-induced lung injury. N Engl J Med 369:2126–2136View ArticlePubMedGoogle Scholar
  2. Pinhu L, Whitehead T, Evans T, Griffiths M (2003) Ventilator-associated lung injury. Lancet 361:332–340View ArticlePubMedGoogle Scholar
  3. Oeckler RA, Hubmayr RD (2007) Ventilator-associated lung injury: a search for better therapeutic targets. Eur Respir J 30:1216–1226View ArticlePubMedGoogle Scholar
  4. Kawano T, Mori S, Cybulsky M, Burger R, Ballin A, Cutz E, Bryan AC (1987) Effect of granulocyte depletion in a ventilated surfactant-depleted lung. J Appl Physiol (1985) 62:27–33View ArticleGoogle Scholar
  5. Bentzer P, Fisher J, Kong HJ, Morgelin M, Boyd JH, Walley KR, Russell JA, Linder A (2016) Heparin-binding protein is important for vascular leak in sepsis. Intensive Care Med Exp 4:33View ArticlePubMedPubMed CentralGoogle Scholar
  6. Linder A, Arnold R, Boyd JH, Zindovic M, Zindovic I, Lange A, Paulsson M, Nyberg P, Russell JA, Pritchard D, Christensson B, Akesson P (2015) Heparin-binding protein measurement improves the prediction of severe infection with organ dysfunction in the emergency department. Crit Care Med 43:2378–2386View ArticlePubMedPubMed CentralGoogle Scholar
  7. Tyden J, Herwald H, Hultin M, Wallden J, Johansson J (2017) Heparin-binding protein as a biomarker of acute kidney injury in critical illness. Acta Anaesthesiol Scand 61:797–803Google Scholar
  8. Johansson J, Brattstrom O, Sjoberg F, Lindbom L, Herwald H, Weitzberg E, Oldner A (2013) Heparin-binding protein (HBP): an early marker of respiratory failure after trauma? Acta Anaesthesiol Scand 57:580–586View ArticlePubMedGoogle Scholar
  9. Lin Q, Shen J, Shen L, Zhang Z, Fu F (2013) Increased plasma levels of heparin-binding protein in patients with acute respiratory distress syndrome. Crit Care 17:R155View ArticlePubMedPubMed CentralGoogle Scholar
  10. Tyden J, Herwald H, Sjoberg F, Johansson J (2016) Increased plasma levels of heparin-binding protein on admission to intensive care are associated with respiratory and circulatory failure. PLoS One 11:e0152035View ArticlePubMedPubMed CentralGoogle Scholar
  11. Chew MS, Linder A, Santen S, Ersson A, Herwald H, Thorlacius H (2012) Increased plasma levels of heparin-binding protein in patients with shock: a prospective, cohort study. Inflamm Res 61:375–379View ArticlePubMedGoogle Scholar
  12. Dankiewicz J, Linder A, Annborn M, Rundgren M, Friberg H (2013) Heparin-binding protein: an early indicator of critical illness and predictor of outcome in cardiac arrest. Resuscitation 84:935–939View ArticlePubMedGoogle Scholar
  13. Fisher J, Russell JA, Bentzer P, Parsons D, Secchia S, Morgelin M, Walley KR, Boyd JH, Linder A (2017) Heparin-binding protein (HBP): a causative marker and potential target for heparin treatment of human sepsis-induced acute kidney injury. Shock 48:313–320View ArticlePubMedGoogle Scholar
  14. Tverring J, Vaara ST, Fisher J, Poukkanen M, Pettila V, Linder A, Group FS (2017) Heparin-binding protein (HBP) improves prediction of sepsis-related acute kidney injury. Ann Intensive Care 7:105View ArticlePubMedPubMed CentralGoogle Scholar
  15. Tapper H, Karlsson A, Morgelin M, Flodgaard H, Herwald H (2002) Secretion of heparin-binding protein from human neutrophils is determined by its localization in azurophilic granules and secretory vesicles. Blood 99:1785–1793View ArticlePubMedGoogle Scholar
  16. Kaukonen KM, Linko R, Herwald H, Lindbom L, Ruokonen E, Ala-Kokko T, Pettila V (2013) Heparin-binding protein (HBP) in critically ill patients with influenza A(H1N1) infection. Clin Microbiol Infect 19:1122–1128View ArticlePubMedGoogle Scholar
  17. McAuley DF, O'Kane CM, Craig TR, Shyamsundar M, Herwald H, Dib K (2013) Simvastatin decreases the level of heparin-binding protein in patients with acute lung injury. BMC Pulm Med 13:47View ArticlePubMedPubMed CentralGoogle Scholar
  18. Dixon B, Santamaria JD, Campbell DJ (2008) A phase 1 trial of nebulised heparin in acute lung injury. Crit Care 12:R64View ArticlePubMedPubMed CentralGoogle Scholar
  19. Murakami K, McGuire R, Cox RA, Jodoin JM, Bjertnaes LJ, Katahira J, Traber LD, Schmalstieg FC, Hawkins HK, Herndon DN, Traber DL (2002) Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock 18:236–241View ArticlePubMedGoogle Scholar
  20. Gunther A, Lubke N, Ermert M, Schermuly RT, Weissmann N, Breithecker A, Markart P, Ruppert C, Quanz K, Ermert L, Grimminger F, Seeger W (2003) Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med 168:1358–1365View ArticlePubMedGoogle Scholar
  21. Gautam N, Olofsson AM, Herwald H, Iversen LF, Lundgren-Akerlund E, Hedqvist P, Arfors KE, Flodgaard H, Lindbom L (2001) Heparin-binding protein (HBP/CAP37): a missing link in neutrophil-evoked alteration of vascular permeability. Nat Med 7:1123–1127View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement